Loading…
Talphera Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -93.3% over 5Y.
today you would have $57.84▼ -94.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 15 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.14 | $0.52 | $0.74 | $2.26 | $11.20 | $24.80 | $42.20 | $46.20 | $40.60 | $52.00 | $77.00 | $134.60 | $226.20 | $85.20 | $38.40 | |
| P/E | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SERSerina Therapeutics, Inc. | $2.46 | — | 3.3x | — | -207.94% | $62.49M |
| BSEMBioStem Technologies, Inc. | $3.53 | 4.0x | 2.3x | — | -74.74% | $62.95M |
| MYOMyomo Inc | $1.60 | — | 10.9x | — | -123.76% | $63.37M |
| HYPDHyperion Defi Inc | $3.92 |
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Company description provided by Yahoo Finance.
| — |
| — |
| 0.4x |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| P/S | 29.2x | 2037.7x | — | 19.3x | — | 29.2x | 27.2x | 74.1x | 84.6x | 12.9x | 6.8x | 9.0x | 56.4x | 16.6x | 65.9x | 35.0x |
| P/B | 4.0x | 3.3x | 1.1x | 0.9x | 1.1x | — | — | — | 42.8x | — | — | 5.3x | 6.3x | 6.7x | 4.7x | 2.2x |
| EPS | -$0.34 | -$0.50 | -$1.29 | $5.72 | -$5.86 | -$9.40 | -$13.40 | -$16.20 | -$22.00 | -$19.00 | -$12.00 | -$18.20 | -$11.80 | -$30.20 | -$23.20 |
| Profit margin | -1245.53% | -51035.71% | — | -2825.96% | — | -1245.53% | -745.55% | -2325.91% | -2191.96% | -644.25% | -248.64% | -126.66% | -639.31% | -79.40% | -1393.61% | -1875.09% |
| ROE | -91.23% | -83.89% | -162.53% | -130.43% | 218.92% | — | — | — | -1108.61% | — | — | -73.68% | -71.49% | -32.02% | -98.57% | -115.07% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.6x |
| — |
| 9.55% |
| $60.84M |
| IMAImageneBio, Inc. | $5.34 | — | 0.4x | — | -82.68% | $60.74M |
| BOLDBoundless Bio, Inc. | $2.83 | — | 1.0x | — | -67.86% | $64.38M |